Steady advancements in simultaneous PET/MR technology make the need for new phantom designs more salient, but the challenge is tricky due to the physics involved in MR imaging. While PET research usually involves watery models, glycols in combination with precise adjustments in tracer composition may be the ideal solution, according to a study published June 21 in the Journal of Nuclear Medicine.

A single-source, dual-energy subtraction CT angiography (CTA) protocol can be optimized to provide fully automatic subtraction of bone and brain parenchyma from contrast-enhanced scans of patients with cerebrovascular disorders, according to a study published June 7 in Academic Radiology.

Men suffering from prostate cancer have a very high chance of developing bone metastases, making it imperative to track and effectively treat local and distant tumors, especially in castrate-resistant cases. Metabolic imaging with FDG PET could provide a biomarker for predicting patients’ survival, which has been found to be a beneficial indicator in the prognosis of patients with this highly variable disease, according to a study published June 19 in the Journal of Nuclear Medicine.

Effective imaging of the formation of new blood vessels feeding invasive tumors is essential to the continued development of antiangiogenetic therapy. A range of imaging methods and antiangiogenic drugs have been developed in this area with inconsistent results, but a technique using 3D MR and avb3-receptor targeted nanoparticles is providing an index of new vessel development over time that could push research forward and potentially improve patient management and outcomes of antiangiogenetic therapy, according to a study published online June 14 in Radiology.

GE Healthcare (NYSE: GE) today announced that it has agreed to acquire certain Mammography assets of Rayence, a subsidiary of Vatech Co Ltd (KOSDAQ: 043150), a Korean X-Ray manufacturer. The Mammography assets of Rayence will, at closing, become part of the Detection & Guidance Solutions (DGS) business unit of GE Healthcare.

Siemens Healthcare, a pioneer in ultrasound innovation, has announced that the Food and Drug Administration (FDA) has cleared the company’s Virtual Touch imaging ultrasound application – Siemens’ first commercially available implementation of Acoustic Radiation Force Impulse (ARFI) technology.

Physicians are bucking the recommendations from multiple specialty societies against the use of neuroimaging for many children presenting with headaches, researchers reported in a study published June 24 in Pediatrics. Although they are common offenders, emergency room physicians aren’t the only providers who appear to be guilty of inappropriate use.

GE Healthcare (NYSE: GE) today announced that it has agreed to acquire certain Mammography assets of Rayence, a subsidiary of Vatech Co Ltd (KOSDAQ: 043150), a Korean X-Ray manufacturer. The Mammography assets of Rayence will, at closing, become part of the Detection & Guidance Solutions (DGS) business unit of GE Healthcare.